An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

And this time, it’s not just fringe actors fanning the flames. It’s policymakers. It’s media personalities. It’s individuals ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

At the start of an unprecedented meeting of vaccine committee of the US Centers for Disease Control and Prevention, the ...

The new variant, NB.1.8.1, is also a subvariant of the Omicron variant. It has spread rapidly, and the earliest sample of ...

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna ...

Dr. Todd Ellerin, Vice Chair of Department of Medicine of South Shore Health discusses the new FDA warning regarding Pfizer ...

Public health community has raised concerns about how the newly-picked vaccine panel may influence decisions going forward.